Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 2Prostatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Leukemia 1Healthy Volunteer 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × keyhole-limpet hemocyanin × Clear all
NCT02745756 2017-08-30

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
CNS

Neoplasms, Neoplasms, Nerve Tissue, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡